Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial

Lung Cancer

Volumn 60, Issue 2, 2008, Pages 252-258

  Sorensen, Morten ^a   Lassen, Ulrik ^a   Palshof, Torben ^b   Jensen, Britta Bjerregaard ^c   Johansen, Jørgen ^d   Jensen, Peter Buhl ^a   Langer, Seppo W ^a  

^a FINSEN LABORATORY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c Esbjerg Sygehus   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Chemoradiation; Limited disease; Lung cancer; Phase II; Small cell lung cancer; Topotecan

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; METOCLOPRAMIDE; METOPIMAZINE; SEROTONIN 3 ANTAGONIST; STEROID; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; ESOPHAGITIS; ESOPHAGUS STRICTURE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPONATREMIA; LEUKOPENIA; LUNG EMBOLISM; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; REMISSION; SEPSIS; SKULL IRRADIATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY, CONFORMAL; TOPOTECAN;

EID: 43049134134     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.09.022     Document Type: Article

References (18)

1. Pignon J.P., Arriagada R., Ihde D.C., Johnson D.H., Perry M.C., Souhami R.L., et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 327 (1992) 1618-1624
2. Turrisi III A.T., Kim K., Blum R., Sause W.T., Livingston R.B., Komaki R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340 (1999) 265-271
3. Schiller J.H., Kim K., Hutson P., DeVore R., Glick J., Stewart J., et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 14 (1996) 2345-2352
4. Ardizzoni A., Hansen H., Dombernowsky P., Gamucci T., Kaplan S., Postmus P., et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15 (1997) 2090-2096
5. von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17 (1999) 658-667
6. Sorensen M., Jensen P.B., Herrstedt J., Hirsch F.R., and Hansen H.H. A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer. Ann Oncol 11 (2000) 829-835
7. Sorensen M., Sehested M., and Jensen P.B. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. Br J Cancer 72 (1995) 399-404
8. Whitacre C.M., Zborowska E., Gordon N.H., Mackay W., and Berger N.A. Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res 57 (1997) 1425-1428
9. Miller A.A., Bogart J.A., Watson D.M., Wang X.F., Rocha Lima C.M., Vokes E.E., et al. Phase II trial of paclitaxel-topotecan-etoposide (PTE) followed by consolidation chemoradiotherapy for limited stage small cell lung cancer (LS-SCLC): CALGB 30002. ASCO Annual Meeting (2005) [Abstract 7170]
10. Bogart J.A., Herndon II J.E., Lyss A.P., Watson D., Miller A.A., Lee M.E., et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys 59 (2004) 460-468
11. Han J.Y., Kwan H.C., Lee D.H., Kim H.Y., Kim E.A., Lee S.Y., et al. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited disease small cell lung cancer. J Clin Oncol 23 (2005) 3488-3494
12. Ettinger D.S., Berkey B.A., Abrams R.A., Fontanesi J., Machtay M., Duncan P.J., et al. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited stage small cell lung cancer: A Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol 23 (2005) 4991-4998
13. Sohn J.H., Moon Y.W., Lee C.G., Kim G.E., Chung K.Y., Chang J., et al. Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer. Cancer 109 (2007) 1845-1850
14. Jeong H.C., Lee S.Y., Lee S.Y., Kim J.H., Shin C., Shim J.J., et al. Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer. Lung Cancer 53 (2006) 361-366
15. Saito H., Takada Y., Ichinose Y., Eguchi K., Kudoh S., Matsui K., et al. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol 24 (2006) 5247-5252
16. Kubota K., Nishiwaki Y., Sugiura T., Noda K., Mori K., Kawahara M., et al. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. Clin Cancer Res 11 (2005) 5534-5538
17. Graham M.V., Jahanzeb M., Dresler C.M., Cooper J.D., Emami B., and Mortimer J.E. Results of a trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable non small cell lung cancer. Int J Radiat Oncol Biol Phys 36 (1996) 1215-1220
18. Bonner J.A., Sloan J.A., Shanahan T.G., Brooks B.J., Marks R.S., Krook J.E., et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 17 (1999) 2681-2691